Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole

Journal of Clinical Pharmacology

Volumn 51, Issue 10, 2011, Pages 1488-1490

  Tsubokura, Masaharu ^a   Miura, Yuji ^a   Itokawa, Tatsuo ^a   Murata, Kazuhiro ^a   Takei, Naoko ^a   Higaki, Tadanao ^a   Murashige, Naoko ^b   Kami, Masahiro ^b   Komatsu, Tsunehiko ^a  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

long QT; QT prolongation; torsades de pointes

Indexed keywords

LANSOPRAZOLE; VORICONAZOLE;

AGED; ARTICLE; CASE REPORT; CHRONIC DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HUMAN; LUNG ASPERGILLOSIS; MALE; POLYMORPHIC VENTRICULAR TACHYCARDIA; QT INTERVAL; QT PROLONGATION; TORSADE DES POINTES;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; ANTI-ULCER AGENTS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG INTERACTIONS; FATAL OUTCOME; HUMANS; MALE; PYRIMIDINES; TACHYCARDIA, VENTRICULAR; TRIAZOLES;

EID: 80053221640     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010384483     Document Type: Article

References (8)

1. Esch JJ, Kantoch MJ. Torsades de pointes ventricular tachycardia in a pediatric patient treated with fluconazole. Pediatr Cardiol. 2008 ; 29: 210-213
2. Pham CP, de Feiter PW, van der Kuy PH, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother. 2006 ; 40: 1456-1461 (Pubitemid 44204980)
3. Alkan Y, Haefeli WE, Burhenne J, Stein J, Yaniv I, Shalit I. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis. 2004 ; 39: e49-e52
4. Jost E, Lorenzen J, Haage P, et al. Heart and muscle involvement by extra-medullary myeloid leukemia: a case report and review of the literature. Leuk Lymphoma. 2005 ; 46: 1819-1824 (Pubitemid 43203119)
5. Philips JA, Marty FM, Stone RM, Koplan BA, Katz JT, Baden LR. Torsades de pointes associated with voriconazole use. Transpl Infect Dis. 2007 ; 9: 33-36
6. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002 ; 46: 2546-2553 (Pubitemid 34793462)
7. Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents. 2006 ; 27: 274-284
8. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet. 1996 ; 31: 9-28 (Pubitemid 26238200)